Kewaunee Scientific Reports Mixed FY26 Results: Sales Up, EPS Down, Significant Debt Reduction
KEQU is trading near its 52-week low of $33.7 (4.7% above the low) on elevated volume (3.9× avg).
Summary
Kewaunee Scientific announced mixed fiscal year 2026 results, featuring strong revenue growth and significant debt reduction, but also a notable decline in full-year and fourth-quarter profitability.
Key Events · Earnings and Guidance · KEQU
-
Full Year Sales Growth
Fiscal year 2026 sales increased by 17.3% to $281.999 million compared to the prior year.
-
Profitability Decline
Full year diluted earnings per share (EPS) decreased by 15.9% to $3.22, down from $3.83 in the prior fiscal year.
-
Weak Fourth Quarter Performance
Fourth quarter sales decreased by 7.5% to $71.4 million, and diluted EPS fell by 30.7% to $1.13, impacted by lower manufacturing volumes and geopolitical disruption.
-
Significant Debt Reduction
The company reduced long-term debt by approximately $20 million, improving its debt-to-equity ratio from 0.99-to-1 to 0.61-to-1.
Analysis · KEQU · Industrial Applications And Services
Kewaunee Scientific reported a strong 17.3% increase in full-year sales to $281.999 million, but diluted earnings per share (EPS) declined by 15.9% to $3.22. The fourth quarter showed a more pronounced slowdown, with sales down 7.5% and EPS falling 30.7%. A significant positive is the reduction of long-term debt by approximately $20 million, substantially improving the company's debt-to-equity ratio. However, the overall order backlog decreased, and the stock is trading near its 52-week low, suggesting investor concern over profitability and future growth despite the balance sheet improvements.
At the time of this filing, KEQU was trading at $35.28 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $101.1M. The 52-week trading range was $33.70 to $60.89. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.